{"id":"W2790263900","doi":"10.1200/jco.2018.36.5_suppl.212","title":"Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Adverse effect; Cohort; Internal medicine; Oncology; Pharmacokinetics; In vivo; Pharmacology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008152864,0.001942154,0.001481359,0.0003818732,0.0004811945,0.001095165,0.0007879651,0.0008692304,0.003971834],"category_scores_gemma":[0.0004959272,0.0005852417,0.0007859363,0.0004680755,0.000875693,0.0006985932,0.0004314145,0.002814119,0.001302504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001239028,"about_ca_system_score_gemma":0.002107935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001629853,"about_ca_topic_score_gemma":0.003412965,"domain_scores_codex":[0.9997343,0.0000923121,0.00001339272,0.00004660765,0.00002888368,0.00008452054],"domain_scores_gemma":[0.9995714,0.00004295414,0.00007663262,0.00002923544,0.00001862633,0.0002612582],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.738704,0.0684023,0.01283107,0.0008246274,0.0009206887,0.0005726476,0.0005086318,0.004060993,0.05024281,0.0006208722,0.006616466,0.1156948],"study_design_scores_gemma":[0.4902032,0.4804463,0.01596577,0.00003830927,0.0004249304,0.0004661608,0.00007616389,0.001670261,0.00603277,0.0002917186,0.00435935,0.00002507823],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909258,0.001232067,0.0004325944,0.0004396369,0.00008486334,0.002989913,0.00126558,0.0001080648,0.002521551],"genre_scores_gemma":[0.9891115,0.0009169739,0.001272499,0.0006699293,0.0001190124,0.002470019,0.002114359,0.00002124842,0.003304408],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003971834,"threshold_uncertainty_score":0.01328713,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07473774142480086,"score_gpt":0.4593583504307734,"score_spread":0.3846206090059725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}